NeuroPace's high P/S ratio is justified by expected strong r...
NeuroPace's high P/S ratio is justified by expected strong revenue growth, outpacing the Medical Equipment industry. Shareholders are optimistic about future revenues, holding onto their shares.
NeuroPace, Inc.'s (NASDAQ:NPCE) P/S Is Still On The Mark Following 34% Share Price Bounce
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment
Moomoo AI Official Account
Your AI assistant for discovering investment opportunities.
3306Followers
0Following
8090Visitors
Follow